标题
Modulatory effects of bortezomib on host immune cell functions
作者
关键词
-
出版物
Immunotherapy
Volume 7, Issue 9, Pages 1011-1022
出版商
Future Medicine Ltd
发表日期
2015-09-01
DOI
10.2217/imt.15.66
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells
- (2013) Xiangling Wang et al. ANTI-CANCER DRUGS
- Bortezomib sensitivity of acute myeloid leukemia CD34+ cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1
- (2013) Matthieu Cornelis Johannes Bosman et al. EXPERIMENTAL HEMATOLOGY
- Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells
- (2013) Jee-Eun Kim et al. PHARMACOLOGICAL RESEARCH
- Proteasome Inhibition Profoundly Affects Activated Human B Cells
- (2013) Arend Mulder et al. TRANSPLANTATION
- Attenuation of Early Atherogenesis in Low-Density Lipoprotein Receptor–Deficient Mice by Proteasome Inhibition
- (2012) Nicola Wilck et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Inhibition of Titanium Particle-Induced Inflammation by the Proteasome Inhibitor Bortezomib in Murine Macrophage-Like RAW 264.7 Cells
- (2012) Xin Mao et al. INFLAMMATION
- Bortezomib regulates the chemotactic characteristics of T cells through downregulation of CXCR3/CXCL9 expression and induction of apoptosis
- (2012) Wei Liu et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells
- (2012) Konstantinos Tsapakidis et al. INTERNATIONAL JOURNAL OF UROLOGY
- Immune Mechanism of the Antitumor Effects Generated by Bortezomib
- (2012) C.-L. Chang et al. JOURNAL OF IMMUNOLOGY
- Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands
- (2012) Laura Jardine et al. LEUKEMIA & LYMPHOMA
- Proteasome Inhibition Blocks NF-κB and ERK1/2 Pathways, Restores Antigen Expression, and Sensitizes Resistant Human Melanoma to TCR-Engineered CTLs
- (2012) Ali R. Jazirehi et al. MOLECULAR CANCER THERAPEUTICS
- Ischemia–reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation
- (2012) Sabarinathan Ramachandran et al. TRANSPLANT IMMUNOLOGY
- Acquired STAT4 deficiency as a consequence of cancer chemotherapy
- (2011) I. P. Lupov et al. BLOOD
- Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
- (2011) S. Arastu-Kapur et al. CLINICAL CANCER RESEARCH
- Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation
- (2011) D Xu et al. LEUKEMIA
- Depletion of alloreactive T-cells in vitro using the proteasome inhibitor bortezomib preserves the immune response against pathogens
- (2011) Belén Blanco et al. LEUKEMIA RESEARCH
- Gamma-secretase inhibitor enhances the cytotoxic effect of bortezomib in multiple myeloma
- (2011) Feng Chen et al. CELLULAR ONCOLOGY
- The Proteasome Inhibitor Bortezomib Sensitizes Melanoma Cells toward Adoptive CTL Attack
- (2010) J. M. Seeger et al. CANCER RESEARCH
- Decrease in CD4+ T-Cell Counts in Patients With Multiple Myeloma Treated With Bortezomib
- (2010) Ulrike Heider et al. Clinical Lymphoma Myeloma & Leukemia
- Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis
- (2010) N. Schmidt et al. GUT
- Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection
- (2010) Seiko Iwata et al. INTERNATIONAL JOURNAL OF CANCER
- The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells
- (2010) Xiaoli Feng et al. MOLECULAR IMMUNOLOGY
- Detrimental Effect of the Proteasome Inhibitor, Bortezomib in Bacterial Superantigen- and Lipopolysaccharide-induced Systemic Inflammation
- (2010) Ashenafi Y Tilahun et al. MOLECULAR THERAPY
- Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy
- (2010) James J. Driscoll et al. Targeted Oncology
- Structure, Assembly and Homeostatic Regulation of the 26S Proteasome
- (2010) Y. Xie Journal of Molecular Cell Biology
- Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells
- (2009) T. Hideshima et al. BLOOD
- Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells
- (2009) A. Lundqvist et al. BLOOD
- Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition
- (2009) E. Ames et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
- (2009) Maria Berg et al. CYTOTHERAPY
- Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population
- (2009) B. Blanco et al. HAEMATOLOGICA
- Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo
- (2009) Elisabeth Zinser et al. IMMUNOBIOLOGY
- Cutting Edge: Bortezomib-Treated Tumors Sensitized to NK Cell Apoptosis Paradoxically Acquire Resistance to Antigen-Specific T Cells
- (2009) A. Lundqvist et al. JOURNAL OF IMMUNOLOGY
- Proteasome Regulation of ULBP1 Transcription
- (2009) James E. Butler et al. JOURNAL OF IMMUNOLOGY
- Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC)
- (2009) Tianhong Li et al. LUNG CANCER
- Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib
- (2008) A. S. M. Yong et al. BLOOD
- ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
- (2008) A. Soriani et al. BLOOD
- Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma
- (2008) S. Armeanu et al. CLINICAL CANCER RESEARCH
- Dampening Ab responses using proteasome inhibitors followingin vivo B cell activation
- (2008) Paolo Cascio et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Proteasome inhibition suppresses essential immune functions of human CD4+T cells
- (2008) Carsten Berges et al. IMMUNOLOGY
- Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study
- (2008) Asher Chanan-Khan et al. JOURNAL OF CLINICAL ONCOLOGY
- Treating Metastatic Solid Tumors With Bortezomib and a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonist Antibody
- (2008) A. Shanker et al. JNCI-Journal of the National Cancer Institute
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now